Remogliflozin Etabonate: First Global Approval.
Drugs. 2019 Jun 14;:
Authors: Markham A
Remogliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor, which is to be administered as remogliflozin etabonate (Remo™, Remozen™), the prodrug for remogliflozin, recently received its first approval as a treatment for type 2 diabetes mellitus (T2DM) in India. This article summarizes the milestones in the development of remogliflozin etabonate leading to this first approval for T2DM.
PMID: 31201711 [PubMed - as supplied by publisher]